FDA to Review Easing Peptide Restrictions as RFK Jr. Endorses Them

The FDA will convene an advisory panel in July to decide whether seven popular injectable peptides should be added to the list allowing pharmacies to compound them, signaling a potential loosening of restrictions on unapproved therapies championed by RFK Jr. While supporters say it could improve access, critics warn of safety risks and the lack of extensive human testing; any change would still require formal rulemaking, and the process may be influenced by Kennedy’s public stance and current agency vacancies.